Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469885 · ClinicalTrials.gov registry record · Phase 2
Reduction of Smoking in Cardiac Disease Patients
A Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 2
- Study locations
NCT00469885 is a Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 152 participants, below the 2,712-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00469885, a Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the effect of smoking reduction vs usual care (quitting advice only) for individuals with peripheral arterial disease who smoke.
Conditions Studied
Interventions
- DRUG Nicotine replacement
- BEHAVIORAL Motivational counseling
Study Locations (2)
Minnesota
- Univeristy of Minnesota - Minneapolis
- Univerisity of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2001-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469885
The ClinicalTrials.gov registry entry for NCT00469885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,712-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (94% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Nicotine replacement is the first listed.
NCT00469885 reports 2 study locations spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00469885 about?
NCT00469885 is a clinical study titled "Reduction of Smoking in Cardiac Disease Patients". This study evaluates the effect of smoking reduction vs usual care (quitting advice only) for individuals with peripheral arterial disease who smoke.
What is the current status of trial NCT00469885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2001-01. Estimated completion is 2005-12.
What conditions does trial NCT00469885 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Tobacco Use Disorder.
What interventions are being tested in trial NCT00469885?
The interventions under investigation include: Nicotine replacement (DRUG), Motivational counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00469885?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00469885 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
The Fibrin Pad Cardiovascular Study
COMPLETED · Phase 2
-
Trial of Oral Glutamine on Mitochondrial Function in CKD
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.